Biotage Receives its Largest Order to Date
News Aug 12, 2005
Biotage has announced that it has received its largest single order to date. It includes 31 instruments and totals approx. 15 MSEK.
The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.
The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.
"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.
He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."
The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019